Entities / Company
Immunocore.
UK business
- Reports this week
- 0
- Active events
- 0
- Connections
- 48
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Cantor Fitzgerald reaffirmed its rating for Immunocore on July 20, 2026.Some support3 reports
-
Zacks Investment Research provided stock analysis reports for Immunocore on August 7, 2025.Some support1 report1 development inside
-
Mizuho set a price target on Immunocore shares.Some support1 report
-
Immunocore's drug KIMMTRAK is being distributed by Er-Kim across Turkey, Caucasus, CIS, and MENA regions.Speculative1 report
-
Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.Some support2 reports
-
Immunocore is providing R&D insights on clinical trial patient management while facing evolving FDA requirements.Some support1 report
-
Immunocore's drug KIMMTRAK received treatment approvals in the UK, US, Canada, and Australia.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Immunocore this week
News at the entities that move Immunocore most-
Cantor Fitzgerald Mentioned togetherCantor Fitzgerald increased its price objective on Intuitive Machines, with MarketBeat providing average ratings and target prices.Moves Immunocore
-
University of Birmingham OperationalA partnership between the University of Lagos and the University of Birmingham will create joint degree programmes supported by the Nigerian government.Moves Immunocore
-
Mizuho Mentioned togetherJefferies Financial Group upgraded its rating on Macerich, while Mizuho also increased its price objective for the company's stock.Moves Immunocore
Connections
The 4 strongest of 48, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Bahija Jallal Structural
Bahija Jallal holds the role of Chief Executive Officer of Immunocore.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provided financial coverage and reaffirmed Immunocore's company rating.
-
Mizuho Mentioned together
Mizuho provided financial analysis, setting a price target on Immunocore shares.
-
University of Birmingham Operational
A representative from the University of Birmingham commented on Immunocore's clinical trial.
History
Events by the month they beganJune 2026
6 events- Zacks Investment Research provided stock analysis reports for Immunocore on August 7, 2025.
- Mizuho set a price target on Immunocore shares.
- Immunocore's drug KIMMTRAK is being distributed by Er-Kim across Turkey, Caucasus, CIS, and MENA regions.
- Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.
- Immunocore is providing R&D insights on clinical trial patient management while facing evolving FDA requirements.
- Immunocore's drug KIMMTRAK received treatment approvals in the UK, US, Canada, and Australia.